New research highlights racial disparities in hemophilia care, revealing that Black and Hispanic patients are significantly less likely to receive immune tolerance induction treatment compared with White patients, even after considering clinical factors.
The results of a new study revealed disparities in hemophilia treatment, specifically immune tolerance induction (ITI) for patients with inhibitors. When accounting for racial and ethnic factors, the researchers observed Black and Hispanic patients received ITI less often than White patients.
According to the study published in Research and Practice in Thrombosis and Haemostasis, in racially diverse communities treatment varies throughout racial and ethnic groups, especially with chronic diseases. This cross-sectional investigation aimed to evaluate health care disparities in hemophilia care based on receipt of ITI among patients with hemophilia and an inhibitor in the United States.
The study, conducted between 2013 and 2017, included 614 participants with severe hemophilia A and an inhibitor who entered the CDC Community Counts registry. The participants were aged 5 years or older at the study entry, and all had a history of an inhibitor.
The analysis assessed the proportion of participants receiving ITI, considering race and ethnicity in both bivariable and multivariable analyses. The latter adjusted for demographic and clinical covariates, with unadjusted and adjusted prevalence ratios (aPRs) and corresponding 95% CIs calculated.
Among the 614 participants, 56.4% were non-Hispanic (NH) White, 19.7% were NH Black, 18.4% were Hispanic, and 4.9% were Asian. Overall, 85.2% of participants received ITI. In the bivariable analysis, ITI treatment did not exhibit significant variations across different racial and ethnic groups.
However, the multivariable analysis revealed notable disparities. Upon further investigation, the study accounted for various clinical factors, including driving distance, hemophilia treatment center (HTC) size, and other relevant variables.
In this adjusted analysis, NH Black and Hispanic participants were found to be statistically significantly less likely to have received ITI (aPR, 0.91; 95% CI, 0.84-0.99) relative to NH White participants (aPR, 0.84; 95% CI, 0.75-0.93), with a 9% and 12% difference, respectively. Asian participants, while showing a nonsignificant trend, were also less likely to receive ITI in adjusted analyses.
The study also explored the aggregated data of NH and non-White participants. When grouped together, this demographic category showed a 12% lower likelihood of receiving ITI compared with NH White participants. This finding indicates that racial and ethnic disparities in ITI treatment exist, even after accounting for various clinical factors.
In analyses specifically focused on participants whose inhibitor was detected when they were 5 years or younger, the proportion receiving ITI treatment was higher at 92.9%. However, even in this subgroup, racial and ethnic differences in ITI treatment persisted, indicating that disparities in treatment patterns extend to early detection scenarios.
As the field of hemophilia care continues to advance, future research should delve deeper into the specific factors contributing to racial disparities in ITI treatment, the researchers noted. Specifically, efforts to address these disparities must extend beyond clinical considerations to encompass the social determinants of health, including systemic biases and cultural competence.
“Although the role of ITI may evolve with growing use of emicizumab and the introduction of new hemophilia treatment products, understanding characteristics that influence care, particularly race and ethnicity where physician bias and patient mistrust can occur, will remain relevant and applicable to other complex therapies, including gene therapy,” they wrote.
Reference
Kempton CL, Payne AB, Fedewa SA. Race, ethnicity, and immune tolerance induction in hemophilia A in the United States. Res Pract Thromb Haemost. Published online November 4, 2023. doi:10.1016/j.rpth.2023.102251
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More